Gastrointestinal Disorders

A pivotal phase 3 clinical trial showed Cologuard significantly more likely than FIT to detect cancerous and advanced precancerous lesions.

Dupilumab, a monoclonal antibody targeting type 2 inflammation, would be the first treatment of its kind for younger children with eosinophilic esophagitis.

Patients hospitalized for Clostridioides difficile infection who also were vitamin D-deficient were at higher risk of recurrence—but lower risk of mortality.

A daily dose of clinical news on Patient Care you may have missed.

Postmenopausal women who consumed 1 or more sugary drinks daily had a nearly 2-fold increased risk of liver cancer in a study of more than 98 000.

Constipation, bloating, and abdominal pain worsening over 1 week bring a woman in her mid-70s to the ED. Labs are normal. What do you see on the CT scan?

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Findings elaborate on the pathophysiological differences in autoimmunity and atrial fibrillation risk between men and women.

Direct-acting antiviral treatment was independently associated with a lower risk of mortality and liver and nonliver outcomes in a large study of adults with chronic hepatitis C.

The analysis of nearly 300 000 individuals found those with IBD were more likely than the general population to have hypertension and that only UC was independently associated.

Your daily dose of clinical news you may have missed.

In patients with IBS-D, 2 types of acupuncture delivered substantial improvements in abdominal pain score and frequency of loose stool after 4 weeks of treatment.

Findings from a new study suggest that supplementing standard care for obesity with butyrate helped reduce BMI, improve glucose metabolism, and reduce inflammation markers.

The single-dose biotherapeutic remained effective through 6 months for more than 90% of phased 3 clinical trial participants, according to Ferring Pharmaceuticals.

Pooled phase 3 data from LIBERTY-EoE-TREET presented at ACAAI 2022 reinforce May 2022 FDA approval of dupilumab for eosinophilic esophagitis.

Identification of unique IBS subsets has implications for more individualized treatment as well as approaches to clinical trials, say study authors.

Your daily dose of clinical news from Patient Care Online.

Over half of induction responder patients who received ustekinumab at maintenance baseline were in symptomatic remission 4 years later, according to data presented at UEG Week 2022.

The woman is in her mid-fifties, diarrhea has been persistent for 10 days and BUQ pain for 2 days. What does the CT show? What's your diagnosis?

The new approval for risankizumab makes it the only interleukin-23 inhibitor for moderately to severely active Crohn disease, according to AbbVie.

Dupilumab is approved for the treatment of eosinophilic esophagitis in patients aged ≥12 years weighing at least 40 kgs.

In a new study of patients with cirrhosis, over two-thirds of outpatient clinic visits that included an opioid prescription were with primary care physicians.

IDWeek 2021: A new study found that only 16% of patients with CDI rehospitalized for recurrent infection had been seen in follow-up 30 days after original discharge.

IDWeek 2021: Use of vancomycin vs metronidazole increased after the 2017 IDSA recommendation but CDI recurrence rates increased slightly, investigators report.

Helicobacter pylori infection in early-middle-aged adults was associated with higher BMI, triglyceride levels, carotid plaque formation, and carotid intima-media thickness.

Intermittent pain causing the child to cry and an episode of bright red rectal bleeding are described by the mother. Review labs and imaging: What's your diagnosis?

The 2021 American College of Gastroenterology guidelines on management of C. difficile reflect an expanding body of evidence for preventing, diagnosing, and treating the dangerous infection.

The investigational, live biotherapeutic demonstrated superior efficacy vs placebo in reduction of recurrent Clostridioides difficile infection in ~100 patients at 8-week follow-up.

The patient says the pain is worse with movement or coughing. He reports no nausea, vomiting, fever, diarrhea, or other complaints. What's your diagnosis?